|
Feb 20
|
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%
|
|
Feb 7
|
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
|
|
Feb 7
|
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
|
|
Jan 8
|
uniQure Announces Pricing of its Public Offering
|
|
Jan 7
|
uniQure Announces Proposed Public Offering
|
|
Sep 23
|
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
|
|
Aug 3
|
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
|
|
Aug 1
|
UniQure restructuring to claim 300 jobs
|
|
Aug 1
|
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 1
|
UniQure: Q2 Earnings Snapshot
|
|
Aug 1
|
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
|
|
Jul 26
|
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
|
|
Jul 23
|
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
|
|
May 9
|
uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 7
|
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
|
|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Dec 19
|
Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
|
|
Dec 19
|
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
|
|
Dec 12
|
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|